{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:34:56Z","timestamp":1789126496894,"version":"build-2803163510"},"reference-count":176,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ccm.2022.10.009","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T18:44:23Z","timestamp":1675968263000},"page":"121-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Conventional and Novel Approaches to Immunosuppression in Lung Transplantation"],"prefix":"10.1016","volume":"44","author":[{"given":"Caroline M.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Ronan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Lyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ccm.2022.10.009_bib1","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jama.1914.02560440015005","article-title":"Heteroplastic tissue grafting effected through roentgen-ray lymphoid destruction","volume":"LXII","author":"Murphy","year":"1914","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/89706","article-title":"The lymphocyte in immunology: from James B. Murphy to James L. Gowans","volume":"2","author":"Silverstein","year":"2001","journal-title":"Nat Immunol"},{"issue":"7121","key":"10.1016\/j.ccm.2022.10.009_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(60)90343-3","article-title":"The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine","volume":"1","author":"Calne","year":"1960","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1172\/JCI104116","article-title":"The effects of 6-mercaptopurine on homograft reactions","volume":"39","author":"Schwartz","year":"1960","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccm.2022.10.009_bib5","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM196306132682401","article-title":"Prolonged survival of human-kidney homografts by immunosuppressive drug therapy","volume":"268","author":"Murray","year":"1963","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2022.10.009_bib6","first-page":"385","article-title":"The reversal of rejection in human renal homografts with subsequent development of homograft tolerance","volume":"117","author":"Starzl","year":"1963","journal-title":"Surg Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporine A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"issue":"8151","key":"10.1016\/j.ccm.2022.10.009_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"issue":"6268","key":"10.1016\/j.ccm.2022.10.009_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/bmj.282.6268.934","article-title":"Cyclosporine A in cadaveric organ transplantation","volume":"282","author":"Calne","year":"1981","journal-title":"Br Med J (Clin Res Ed"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib10","first-page":"17","article-title":"The use of cyclosporine A and prednisone in cadaver kidney transplantation","volume":"151","author":"Starzl","year":"1980","journal-title":"Surg Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJM198107303050507","article-title":"Liver transplantation with use of cyclosporine A and prednisone","volume":"305","author":"Starzl","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"8670","key":"10.1016\/j.ccm.2022.10.009_bib12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2022.10.009_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM198203113061001","article-title":"Heart lung transplantation: successful therapy for patients with pulmonary vascular disease","volume":"306","author":"Reitz","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2022.10.009_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-5223(19)36439-6","article-title":"Technique of successful lung transplantation in humans","volume":"93","author":"Cooper","year":"1987","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1586\/1744666X.2014.959499","article-title":"Lung transplant immunosuppression - time for a new approach?","volume":"10","author":"Witt","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MOT.0000000000000871","article-title":"Tolerance, immunosuppression, and immune modulation: impacts on lung allograft survival","volume":"26","author":"Shepherd","year":"2021","journal-title":"Curr Opin Organ Transpl"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2741\/3330","article-title":"Immunosuppression for lung transplantation","volume":"14","author":"Ng","year":"2009","journal-title":"Front Biosci (Landmark Ed"},{"key":"10.1016\/j.ccm.2022.10.009_bib19","doi-asserted-by":"crossref","first-page":"845867","DOI":"10.3389\/fimmu.2022.845867","article-title":"B\u00a0cell immunity in lung transplant rejection - effector mechanisms and therapeutic implications","volume":"13","author":"Ohm","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ccm.2022.10.009_bib20","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.4049\/jimmunol.1102830","article-title":"Germinal center Alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells","volume":"188","author":"Conlon","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib21","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1097\/TP.0000000000001217","article-title":"T\u00a0follicular helper cells in transplantation","volume":"100","author":"Walters","year":"2016","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3227","article-title":"Regulatory immune cells in transplantation","volume":"12","author":"Wood","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ccm.2022.10.009_bib23","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.3389\/fimmu.2018.02548","article-title":"T\u00a0cell allorecognition pathways in solid organ transplantation","volume":"9","author":"Siu","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ajt.14600","article-title":"Review: the transcripts associated with organ allograft rejection","volume":"18","author":"Halloran","year":"2018","journal-title":"Am J Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib25","doi-asserted-by":"crossref","first-page":"750754","DOI":"10.3389\/fimmu.2021.750754","article-title":"Advanced genomics-based approaches for defining allograft rejection with single cell resolution","volume":"12","author":"Shi","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib26","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1038\/s41598-022-10866-w","article-title":"Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation","volume":"12","author":"Benazzo","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ccm.2022.10.009_bib27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match","volume":"38","author":"Chambers","year":"2019","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.healun.2018.07.020","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: multiorgan transplantation","volume":"37","author":"Chambers","year":"2018","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1432-2277.2006.00343.x","article-title":"The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation","volume":"19","author":"Magliocca","year":"2006","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5500\/wjt.v5.i4.261","article-title":"Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation","volume":"5","author":"Ippoliti","year":"2015","journal-title":"World J Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1399-0012.2008.00831.x","article-title":"The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry","volume":"22","author":"Hachem","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib32","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/ajt.13739","article-title":"The impact of Alemtuzumab and Basliliximab Induction on patient survival and time to bronchitis obliterates syndrome in double lung transplantation recipients","volume":"16","author":"Furuya","year":"2016","journal-title":"Am J Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib33","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/ajt.12824","article-title":"Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study","volume":"14","author":"Jaksch","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.healun.2011.01.714","article-title":"Five-year outcomes with alemtuzumab induction after lung transplantation","volume":"30","author":"Shyu","year":"2011","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"10","key":"10.1016\/j.ccm.2022.10.009_bib35","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","article-title":"Alemtuzumab (Campath-1H): a systematic review in organ transplantation","volume":"81","author":"Morris","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib37","first-page":"CD008927","article-title":"Antibody induction therapy for lung transplant recipients","volume":"2013","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/ajt.12663","article-title":"A\u00a0randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation","volume":"14","author":"Snell","year":"2014","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib39","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.transproceed.2008.11.016","article-title":"Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis","volume":"41","author":"Fan","year":"2009","journal-title":"Transpl Proc"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.healun.2012.03.008","article-title":"Tacrolimus and cyclosporinee have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation","volume":"31","author":"Treede","year":"2012","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"10","key":"10.1016\/j.ccm.2022.10.009_bib41","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1016\/j.transproceed.2010.09.126","article-title":"Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study","volume":"42","author":"Collin","year":"2010","journal-title":"Transpl Proc"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1432-2277.2011.01254.x","article-title":"Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation","volume":"24","author":"Beckebaum","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.ccm.2022.10.009_bib43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/DDDT.S52820","article-title":"Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation","volume":"7","author":"Doesch","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib44","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.transproceed.2011.07.014","article-title":"Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation","volume":"43","author":"Kolonko","year":"2011","journal-title":"Transpl Proc"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib45","first-page":"CD007746","article-title":"Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients","volume":"3","author":"Wagner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib46","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/00007890-200106270-00012","article-title":"Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection","volume":"71","author":"Palmer","year":"2001","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib47","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/01.tp.0000202755.33883.61","article-title":"Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients","volume":"81","author":"McNeil","year":"2006","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.healun.2018.03.012","article-title":"Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation","volume":"37","author":"Vos","year":"2018","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1472-8206.2009.00711.x","article-title":"EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects","volume":"23","author":"Sabbatini","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: quintiles prize lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ccm.2022.10.009_bib52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201005-0775OC","article-title":"Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation","volume":"183","author":"Bhorade","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2022.10.009_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2005.01134.x","article-title":"Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial","volume":"6","author":"Snell","year":"2006","journal-title":"Am J Transpl"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib55","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial","volume":"16","author":"Strueber","year":"2016","journal-title":"Am J Transpl"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib56","doi-asserted-by":"crossref","first-page":"e1910297","DOI":"10.1001\/jamanetworkopen.2019.10297","article-title":"Survival associated with sirolimus plus tacrolimus maintenance without induction therapy compared with standard immunosuppression after lung transplant","volume":"2","author":"Wijesinha","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ccm.2022.10.009_bib57","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib58","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1053\/j.ajkd.2006.01.029","article-title":"Sirolimus-induced remission of posttransplantation lymphoproliferative disorder","volume":"47","author":"Cullis","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1053-2498(03)00309-7","article-title":"Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression","volume":"23","author":"Groetzner","year":"2004","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib60","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/01.TP.0000064083.02120.2C","article-title":"Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation","volume":"75","author":"King-Biggs","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib61","first-page":"305931","article-title":"Interstitial lung disease associated with mTOR inhibitors in solid organ transplant recipients: results from a large phase III clinical trial program of everolimus and review of the literature","volume":"2014","author":"Lopez","year":"2014","journal-title":"J\u00a0Transpl"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib62","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","article-title":"Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus","volume":"42","author":"S\u00e1nchez-Fructuoso","year":"2010","journal-title":"Transpl Proc"},{"key":"10.1016\/j.ccm.2022.10.009_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":"Recommendations on the use of everolimus in lung transplantation","volume":"27","author":"de Pablo","year":"2013","journal-title":"Transpl Rev (Orlando)"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib64","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1183\/09031936.00107514","article-title":"An international ISHLT\/ATS\/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome","volume":"44","author":"Meyer","year":"2014","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.healun.2017.05.030","article-title":"Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: a systematic review","volume":"36","author":"Benden","year":"2017","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/TP.0b013e31824db9da","article-title":"Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection","volume":"94","author":"Vos","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib67","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/01.TP.0000122412.80864.43","article-title":"Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation","volume":"77","author":"Verleden","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib68","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200601-071OC","article-title":"Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome","volume":"174","author":"Verleden","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.tp.0000295981.84633.bc","article-title":"Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation","volume":"85","author":"Gottlieb","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib70","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.healun.2010.05.023","article-title":"Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?","volume":"29","author":"Vos","year":"2010","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib71","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ctr.12401","article-title":"Azithromycin improves lung function in patients with post-lung transplant bronchiolitis obliterans syndrome: a meta-analysis","volume":"28","author":"Kingah","year":"2014","journal-title":"Clin Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.healun.2009.12.003","article-title":"Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome","volume":"29","author":"Jain","year":"2010","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib73","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1183\/09031936.00068310","article-title":"A\u00a0randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation","volume":"37","author":"Vos","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.transproceed.2006.10.227","article-title":"Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients","volume":"39","author":"Meloni","year":"2007","journal-title":"Transpl Proc"},{"key":"10.1016\/j.ccm.2022.10.009_bib75","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.healun.2008.02.015","article-title":"Role for CD4 CD25 T cells in inhibition of graft rejection by extracorporeal photopheresis","volume":"27","author":"George","year":"2008","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib76","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-11-125542","article-title":"Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells","volume":"112","author":"Gatza","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib77","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0000000000002168","article-title":"Extracorporeal photopheresis for bronchiolitis obliterans syndrome after lung transplantation","volume":"102","author":"Hachem","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib78","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/TP.0b013e31818bc024","article-title":"Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience","volume":"86","author":"Benden","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib79","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.healun.2009.08.029","article-title":"The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation","volume":"29","author":"Morrell","year":"2010","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib80","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.healun.2012.05.002","article-title":"A\u00a0prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation","volume":"31","author":"Jaksch","year":"2012","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib81","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000431382","article-title":"Long-term off-line extracorporeal photochemotherapy in patients with chronic lung allograft rejection not responsive to conventional treatment: a 10-year single-centre analysis","volume":"90","author":"Del Fante","year":"2015","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib82","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.transproceed.2017.02.035","article-title":"Efficacy of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation","volume":"49","author":"Pecoraro","year":"2017","journal-title":"Transpl Proc"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib83","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/ajt.12155","article-title":"Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients","volume":"13","author":"Greer","year":"2013","journal-title":"Am J Transpl"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0009-9260(85)80094-5","article-title":"Total lymphoid irradiation as an immunosuppressive agent for transplantation and the treatment of 'autoimmune' disease: a review","volume":"36","author":"Halperin","year":"1985","journal-title":"Clin Radiol"},{"key":"10.1016\/j.ccm.2022.10.009_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00113-8","article-title":"Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation","volume":"41","author":"Diamond","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ccm.2022.10.009_bib86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1600-6143.2004.00709.x","article-title":"The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation","volume":"5","author":"Fisher","year":"2005","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib87","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.transproceed.2009.03.070","article-title":"Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation","volume":"41","author":"Verleden","year":"2009","journal-title":"Transpl Proc"},{"issue":"S4","key":"10.1016\/j.ccm.2022.10.009_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.healun.2016.01.191","article-title":"Total lymphoid irradiation (TLI) for the management of bronchiolitis obliterans syndrome (BOS) post lung transplant: a single centre experience [abstract]","volume":"35","author":"Miller","year":"2016","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib89","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tri.13544","article-title":"Total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation: a single-center experience and review of literature","volume":"33","author":"Lebeer","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.ccm.2022.10.009_bib90","doi-asserted-by":"crossref","first-page":"e0193564","DOI":"10.1371\/journal.pone.0193564","article-title":"Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a randomized controlled trial","volume":"13","author":"Ruttens","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib91","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.healun.2018.11.014","article-title":"Montelukast in chronic lung allograft dysfunction after lung transplantation","volume":"38","author":"Vos","year":"2019","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib92","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/ajrccm.153.4.8616581","article-title":"Aerosolized cyclosporine in lung recipients with refractory chronic rejection","volume":"153","author":"Iacono","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2022.10.009_bib93","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1183\/09031936.04.00058504","article-title":"Aerosol cyclosporine therapy in lung transplant recipients with bronchiolitis obliterans","volume":"23","author":"Iacono","year":"2004","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa043204","article-title":"A\u00a0randomized trial of inhaled cyclosporine in lung-transplant recipients","volume":"354","author":"Iacono","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/ajt.16858","article-title":"A\u00a0randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation","volume":"22","author":"Neurohr","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib96","doi-asserted-by":"crossref","first-page":"00167","DOI":"10.1183\/23120541.00167-2019","article-title":"A\u00a0randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation","volume":"5","author":"Iacono","year":"2019","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib97","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1165\/rcmb.2009-0208OC","article-title":"Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation","volume":"43","author":"Deuse","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib98","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/pharmaceutics13050717","article-title":"A\u00a0safety and tolerability study of thin film freeze-dried tacrolimus for local pulmonary drug delivery in human subjects","volume":"13","author":"Sahakijpijarn","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib99","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.transproceed.2010.08.029","article-title":"Aerosolized tacrolimus: a case report in a lung transplant recipient","volume":"42","author":"Hayes","year":"2010","journal-title":"Transpl Proc"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/TP.0b013e318225670d","article-title":"Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation--a propensity score analysis with 23 years of follow-up","volume":"92","author":"Li","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13156","article-title":"Effect of HMG CoA reductase inhibitors on the development of chronic lung allograft dysfunction","volume":"32","author":"Szczepanik","year":"2018","journal-title":"Clin Transpl"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib102","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/ajt.15378","article-title":"Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation","volume":"19","author":"Veit","year":"2019","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib103","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.healun.2013.02.004","article-title":"Pirfenidone: a potential therapy for progressive lung allograft dysfunction?","volume":"32","author":"Ihle","year":"2013","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib104","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.12474","article-title":"Pirfenidone: a potential new therapy for restrictive allograft syndrome?","volume":"13","author":"Vos","year":"2013","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib105","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1111\/ajt.15019","article-title":"Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series","volume":"18","author":"Vos","year":"2018","journal-title":"Am J Transpl"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib106","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cmi.2016.04.007","article-title":"Torquetenovirus: the human virome from bench to bedside","volume":"22","author":"Focosi","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/rmv.524","article-title":"Torque teno virus (TTV): current status","volume":"17","author":"Hino","year":"2007","journal-title":"Rev Med Virol"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib108","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.cell.2013.10.034","article-title":"Temporal response of the human virome to immunosuppression and antiviral therapy","volume":"155","author":"De Vlaminck","year":"2013","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib109","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/infdis\/jiy452","article-title":"Torque teno virus as a novel biomarker targeting the efficacy of immunosuppression after lung transplantation","volume":"218","author":"Jaksch","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib110","doi-asserted-by":"crossref","first-page":"e13778","DOI":"10.1111\/tid.13778","article-title":"Viruses, friends, and foes: the case of Torque Teno Virus and the net state of immunosuppression","volume":"24","author":"Redondo","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ccm.2022.10.009_bib111","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/1745-6215-15-324","volume":"15","author":"Ahlenstiel-Grunow","year":"2014","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib112","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/ajt.13684","article-title":"The \"ABC\" of virus-specific T cell immunity in solid organ transplantation","volume":"16","author":"Sester","year":"2016","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib113","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2012.05.012","article-title":"Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes","volume":"31","author":"Shino","year":"2012","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.ccm.2022.10.009_bib114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trim.2016.04.001","article-title":"Clinical utility of CD4+ function assessment (ViraCor-IBT ImmuKnow test) in lung recipients","volume":"37","author":"Piloni","year":"2016","journal-title":"Transpl Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib115","doi-asserted-by":"crossref","first-page":"e13550","DOI":"10.1111\/tid.13550","article-title":"Evaluation of Quantiferon\u00ae-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients","volume":"23","author":"Gardiner","year":"2021","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib116","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/cid\/cix1008","article-title":"Evaluation of a novel global immunity assay to predict infection in organ transplant recipients","volume":"66","author":"Mian","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib117","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/TP.0000000000000650","article-title":"Immunosuppression modifications based on an immune response assay: results of a randomized, controlled trial","volume":"99","author":"Ravaioli","year":"2015","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13063-020-04985-w","article-title":"Viral load-guided immunosuppression after lung transplantation (VIGILung)-study protocol for a randomized controlled trial","volume":"22","author":"Gottlieb","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1432-2277.2012.01570.x","article-title":"Antithymocyte globulin induction therapy improves survival in lung transplantation for cystic fibrosis","volume":"26","author":"Jaksch","year":"2013","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jcf.2014.05.010","article-title":"Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients","volume":"14","author":"Kirkby","year":"2015","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib121","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.trim.2005.08.001","article-title":"Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 \u22173\/\u22173 non-expressors","volume":"15","author":"Wang","year":"2006","journal-title":"Transpl Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib122","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ccm.2022.10.009_bib123","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s40064-015-1425-5","article-title":"CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients","volume":"4","author":"Li","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.ccm.2022.10.009_bib124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3389\/fgene.2020.00889","article-title":"Beyond single nucleotide polymorphisms: CYP3A5\u22173\u22176\u22177 composite and ABCB1 haplotype Associations to tacrolimus pharmacokinetics in black and white renal transplant recipients","volume":"11","author":"Brazeau","year":"2020","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000028394","article-title":"Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance","volume":"61","author":"Krynetski","year":"2000","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib126","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cts.13243","article-title":"Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity","volume":"15","author":"Daniel","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib127","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1183\/09031936.00060014","article-title":"Lung transplantation in telomerase mutation carriers with pulmonary fibrosis","volume":"44","author":"Silhan","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.healun.2014.11.010","article-title":"Severe hematologic complications after lung transplantation in patients with telomerase complex mutations","volume":"34","author":"Borie","year":"2015","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib129","first-page":"122","article-title":"Strategies for the prevention of invasive fungal infections after lung transplant","volume":"7","author":"Bitterman","year":"2021","journal-title":"J\u00a0Fungi (Basel)"},{"issue":"10","key":"10.1016\/j.ccm.2022.10.009_bib130","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/ajt.12401","article-title":"What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis","volume":"13","author":"Florescu","year":"2013","journal-title":"Am J Transpl"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib131","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1097\/TXD.0000000000000811","article-title":"A\u00a0prospective observational study of hypogammaglobulinemia in the first year after lung transplantation","volume":"4","author":"Petrov","year":"2018","journal-title":"Transpl Direct"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib132","doi-asserted-by":"crossref","first-page":"e103908","DOI":"10.1371\/journal.pone.0103908","article-title":"Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: a randomized crossover trial","volume":"9","author":"Lederer","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib133","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1600-6143.2005.00867.x","article-title":"Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality","volume":"5","author":"Rocha","year":"2005","journal-title":"Am J Transpl"},{"issue":"10","key":"10.1016\/j.ccm.2022.10.009_bib134","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.healun.2011.04.013","article-title":"Severe acute kidney injury according to the RIFLE (risk, injury, failure, loss, end stage) criteria affects mortality in lung transplantation","volume":"30","author":"Arnaoutakis","year":"2011","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib135","first-page":"193","article-title":"Acute renal failure following lung transplantation: risk factors, mortality, and long-term consequences","volume":"41","author":"Jacques","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib136","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.healun.2011.08.016","article-title":"Short-term and long-term outcomes of acute kidney injury after lung transplantation","volume":"31","author":"Wehbe","year":"2012","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib137","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/ndt\/gfu226","article-title":"Incidence and outcomes of acute kidney injury following orthotopic lung transplantation: a population-based cohort study","volume":"29","author":"Fidalgo","year":"2014","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib138","doi-asserted-by":"crossref","first-page":"e0265002","DOI":"10.1371\/journal.pone.0265002","article-title":"Kidney injury after lung transplantation: long-term mortality predicted by post-operative day-7 serum creatinine and few clinical factors","volume":"17","author":"Doricic","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib139","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.athoracsur.2011.11.032","article-title":"Acute kidney injury increases mortality after lung transplantation","volume":"94","author":"George","year":"2012","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib140","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.healun.2007.08.006","article-title":"Dialysis after lung transplantation: prevalence, risk factors and outcome","volume":"26","author":"Mason","year":"2007","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib141","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.semnephrol.2007.03.010","article-title":"Renal disease in recipients of nonrenal solid organ transplantation","volume":"27","author":"Ojo","year":"2007","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib142","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2215\/CJN.04800512","article-title":"Recovery from AKI and short- and long-term outcomes after lung transplantation","volume":"8","author":"Wehbe","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib143","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.kint.2017.02.019","article-title":"Post-discharge kidney function is associated with subsequent ten-year renal progression risk among survivors of acute kidney injury","volume":"92","author":"Sawhney","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib144","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib145","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib146","doi-asserted-by":"crossref","first-page":"e0210443","DOI":"10.1371\/journal.pone.0210443","article-title":"Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: a single centre experience","volume":"14","author":"Benazzo","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib147","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3349\/ymj.2021.62.2.164","article-title":"Basiliximab induction with delayed calcineurin inhibitors for high-risk lung transplant candidates","volume":"62","author":"Kim","year":"2021","journal-title":"Yonsei Med J"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib148","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00007890-200204150-00030","article-title":"Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor \"holiday\" in solid organ transplant patients with acute renal dysfunction","volume":"73","author":"Cantarovich","year":"2002","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib149","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5301\/HEART.2014.12526","article-title":"Use of a \"CNI holidays\" strategy in acute renal dysfunction late after heart transplant. Report of two cases","volume":"9","author":"Alonso","year":"2014","journal-title":"Heart Int"},{"issue":"6","key":"10.1016\/j.ccm.2022.10.009_bib150","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A\u00a0randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transpl"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib151","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tri.12783","article-title":"Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial","volume":"29","author":"Gullestad","year":"2016","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib152","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13063-020-04843-9","article-title":"Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation","volume":"22","author":"Benazzo","year":"2021","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib153","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/tri.12731","article-title":"Belatacept for renal rescue in lung transplant patients","volume":"29","author":"Timofte","year":"2016","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib154","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib155","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","article-title":"Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (highdes)","volume":"105","author":"Jordan","year":"2021","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib156","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transpl"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14728214.2022.2091131","article-title":"Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials","volume":"27","author":"Mayer","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"issue":"8","key":"10.1016\/j.ccm.2022.10.009_bib158","doi-asserted-by":"crossref","first-page":"e14734","DOI":"10.1111\/ctr.14734","article-title":"Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients","volume":"36","author":"Pearl","year":"2022","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/TP.0000000000001452","article-title":"Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade","volume":"101","author":"Jordan","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2022.10.009_bib160","first-page":"111","article-title":"CD28 co-stimulation in T-cell homeostasis: a recent perspective","volume":"4","author":"Beyersdorf","year":"2015","journal-title":"Immunotargets Ther"},{"issue":"3","key":"10.1016\/j.ccm.2022.10.009_bib161","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A\u00a0phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1016\/j.ccm.2022.10.009_bib162","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccm.2022.10.009_bib163","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib164","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nm1688","article-title":"Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes","volume":"14","author":"Joffre","year":"2008","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.ccm.2022.10.009_bib165","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"B\u00e9zie","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ccm.2022.10.009_bib166","doi-asserted-by":"crossref","first-page":"686439","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib167","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A\u00a0pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ccm.2022.10.009_bib168","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.humimm.2017.11.008","article-title":"Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach","volume":"79","author":"Sasaki","year":"2018","journal-title":"Hum Immunol"},{"issue":"7","key":"10.1016\/j.ccm.2022.10.009_bib169","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/TP.0000000000003006","article-title":"Inducing transient mixed chimerism for allograft survival without maintenance immunosuppression with combined kidney and bone marrow transplantation: protocol optimization","volume":"104","author":"Lee","year":"2020","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ccm.2022.10.009_bib170","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2014.07.058","article-title":"Tolerance and immunity after sequential lung and bone marrow transplantation from an unrelated cadaveric donor","volume":"135","author":"Szabolcs","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2022.10.009_bib171","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.16139","article-title":"The fourth international workshop on clinical transplant tolerance","volume":"21","author":"Issa","year":"2021","journal-title":"Am J Transpl"},{"issue":"12","key":"10.1016\/j.ccm.2022.10.009_bib172","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1111\/ajt.16784","article-title":"The potential of ex\u00a0vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury","volume":"21","author":"Iske","year":"2021","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib173","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1097\/TP.0000000000003237","article-title":"Cyclosporin A administration during ex\u00a0vivo lung perfusion preserves lung grafts in rat transplant model","volume":"104","author":"Haam","year":"2020","journal-title":"Transplantation"},{"issue":"632","key":"10.1016\/j.ccm.2022.10.009_bib174","doi-asserted-by":"crossref","first-page":"eabm7190","DOI":"10.1126\/scitranslmed.abm7190","article-title":"Ex\u00a0vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs","volume":"14","author":"Wang","year":"2022","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.ccm.2022.10.009_bib175","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1097\/TP.0000000000003237","article-title":"Cyclosporin A Administration During Ex Vivo Lung Perfusion Preserves Lung Grafts in Rat Transplant Model","volume":"104","author":"Haam","year":"2020","journal-title":"Transplantation"},{"issue":"632","key":"10.1016\/j.ccm.2022.10.009_bib176","doi-asserted-by":"crossref","first-page":"eabm7190","DOI":"10.1126\/scitranslmed.abm7190","article-title":"Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs","volume":"14","author":"Wang","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523122001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523122001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:16:17Z","timestamp":1759454177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523122001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":176,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0272523122001113"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2022.10.009","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conventional and Novel Approaches to Immunosuppression in Lung Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}